Alexis LeVee, Breast Medical Oncologist, UCLA Health, shared a post on X:
“Another positive trial in 1L HER2+ MBC!
HER2CLIMB-05 just reported that adding the oral TKI tucatinib improved PFS in the maintenance setting (with HP) in 1L HER2+ breast cancer.
Results to be presented at SABCS25.”
More posts featuring Alexis LeVee.